Suberoylanilide hydroxamic acid suppresses hepatic stellate cells activation by HMGB1 dependent reduction of NF-κB1

Suberoylanilide hydroxamic acid suppresses hepatic stellate cells activation by HMGB1 dependent reduction of NF-κB1

Hepatic stellate cells (HSCs) activation is essential to the pathogenesis of liver fibrosis. Exploring drugs targeting HSC activation is a promising anti-fibrotic strategy. In the present study, we found suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, prominently suppressed...

Full description

Bibliographic Details
Main Authors:	Wenwen Wang, Min Yan, Qiuhong Ji, Jinbiao Lu, Yuhua Ji, Juling Ji
Format:	Article
Language:	English
Published:	PeerJ Inc. 2015-11-01
Series:	PeerJ
Subjects:	Hepatic stellate cell Histone deacetylase inhibitor Liver fibrosis Suberoylanilide hydroxamic acid Nuclear factor kappa B1 High mobility group box 1
Online Access:	https://peerj.com/articles/1362.pdf

Similar Items

ING5‐mediated antineuroblastoma effects of suberoylanilide hydroxamic acid
by: Ji‐cheng Wu, et al.
Published: (2018-09-01)

In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model
by: Thiemann Markus, et al.
Published: (2012-03-01)

Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines
by: Kulozik Andreas E, et al.
Published: (2011-09-01)

Histone deacetylase inhibition by suberoylanilide hydroxamic acid during reperfusion promotes multifaceted brain and vascular protection in spontaneously hypertensive rats with transient ischaemic stroke
by: Andrea Díaz-Pérez, et al.
Published: (2024-03-01)

In vivo inhibitory effect of suberoylanilide hydroxamic acid combined with sorafenib on human hepatocellular carcinoma cells
by: Dalin Hao, et al.
Published: (2020-03-01)

Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells
by: Sonia Abou Najem, et al.
Published: (2019-11-01)

Histone Deacetylase Inhibitor SAHA Improves High Salinity Tolerance Associated with Hyperacetylation-Enhancing Expression of Ion Homeostasis-Related Genes in Cotton
by: Shibin He, et al.
Published: (2020-09-01)

Suberoylanilide Hydroxamic Acid (SAHA) Treatment Reveals Crosstalk Among Proteome, Phosphoproteome, and Acetylome in Nasopharyngeal Carcinoma Cells
by: Huichao Huang, et al.
Published: (2022-05-01)

Vorinostat (SAHA) and Breast Cancer: An Overview
by: Anna Wawruszak, et al.
Published: (2021-09-01)

Hydroxamic acid - A novel molecule for anticancer therapy
by: Dilipkumar Pal, et al.
Published: (2012-01-01)

p53-Mediated Molecular Control of Autophagy in Tumor Cells
by: Maria Mrakovcic, et al.
Published: (2018-03-01)

Dissection of Anti-tumor Activity of Histone Deacetylase Inhibitor SAHA in Nasopharyngeal Carcinoma Cells via Quantitative Phosphoproteomics
by: Huichao Huang, et al.
Published: (2020-11-01)

Preclinical Studies in the mdx Mouse Model of Duchenne Muscular Dystrophy with the Histone Deacetylase Inhibitor Givinostat
by: Silvia Consalvi, et al.
Published: (2013-03-01)

Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
by: Anton Frühauf, et al.
Published: (2021-08-01)

Hydroxamic Acid as a Potent Metal-Binding Group for Inhibiting Tyrosinase
by: Joonhyeok Choi, et al.
Published: (2022-01-01)

Design, Synthesis and Biological Evaluation of Hydroxamic Acid Derivatives as Potential High Density Lipoprotein (HDL) Receptor CLA-1 Up-Regulating Agents
by: Yu Du, et al.
Published: (2011-11-01)

Effects and related mechanisms of histone deacetylase inhibitors on the proliferation of choroidal melanoma C918 cell line
by: Yi-Meng Zhang, et al.
Published: (2023-02-01)

A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma
by: Hao Wang, et al.
Published: (2021-11-01)

Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
by: Marinella Zilli, et al.
Published: (2013-07-01)

Thiết kế, tổng hợp và đánh giá khả năng ức chế enzyme histone deacetylase (HDAC) in silico của một số dẫn xuất tương tự belinostat
by: Nguyễn Cường Quốc, et al.
Published: (2020-06-01)

Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure
by: Xiaodi Qiu, et al.
Published: (2019-02-01)

Hydroxamate-Based Histone Deacetylase Inhibitors as Potential Mediators to Induce Dentine Regeneration by Human Dental Pulp Cell
by: Indrani Sulistyowati, et al.
Published: (2021-10-01)

Targeting developmental regulators of zebrafish exocrine pancreas as a therapeutic approach in human pancreatic cancer
by: Nelson S. Yee, et al.
Published: (2012-02-01)

The Importance of the “Time Factor” for the Evaluation of Inhibition Mechanisms: The Case of Selected HDAC6 Inhibitors
by: Edoardo Cellupica, et al.
Published: (2023-07-01)

NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells
by: Jih-Tung Pai, et al.
Published: (2015-05-01)

Changes in the Expression of TBP-2 in Response to Histone Deacetylase Inhibitor Treatment in Human Endometrial Cells
by: Hye In Kim, et al.
Published: (2021-01-01)

Application of Electric Cell-Substrate Impedance Sensing to Investigate the Cytotoxic Effects of Andrographolide on U-87 MG Glioblastoma Cell Migration and Apoptosis
by: Sheng-Po Chiu, et al.
Published: (2019-05-01)

Opportunities and Difficulties in the Repurposing of HDAC Inhibitors as Antiparasitic Agents
by: Tapas Kumar Mohapatra, et al.
Published: (2024-01-01)

Multimodal nanoparticle‐containing modified suberoylanilide hydroxamic acid polymer conjugates to mitigate immune dysfunction in severe inflammation
by: Nhu Truong, et al.
Published: (2024-01-01)

Inhibition of histone-deacetylase activity rescues inflammatory cystic fibrosis lung disease by modulating innate and adaptive immune responses
by: Manish Bodas, et al.
Published: (2018-01-01)

Effectiveness of an <i>O</i>-Alkyl Hydroxamate in Dogs with Naturally Acquired Canine Leishmaniosis: An Exploratory Clinical Trial
by: Victoriano Corpas-López, et al.
Published: (2022-10-01)

Elaboration of the Effective Multi-Target Therapeutic Platform for the Treatment of Alzheimer’s Disease Based on Novel Monoterpene-Derived Hydroxamic Acids
by: Yulia Aleksandrova, et al.
Published: (2023-06-01)

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
by: Cristina Maccallini, et al.
Published: (2022-05-01)

Design, synthesis and biological evaluation of novel histone deacetylase inhibitors based on virtual screening
by: Hui Lu, et al.
Published: (2011-12-01)

Exploration of novel 5′(7′)-substituted-2′-
by: Do Thi Mai Dung, et al.
Published: (2017-05-01)

Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Improves Energetic Status and Cardiomyogenic Differentiation of Human Dilated Myocardium-Derived Primary Mesenchymal Cells
by: Rokas Miksiunas, et al.
Published: (2020-07-01)

Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues
by: Bartosz Bieszczad, et al.
Published: (2021-08-01)

HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes
by: Jaspreet Singh, et al.
Published: (2011-11-01)

Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation
by: Dusan Ruzic, et al.
Published: (2022-11-01)

In Silico Profiling of Histone Deacetylase 8 Inhibitory Activity: A Computational Analysis of Novel Dipeptide-Based Compounds Cross-Linked with Hydroxamic Acid
by: omer mohammed ammash, et al.
Published: (2024-04-01)